Clinical trials of stem cell therapy for ischemic stroke: a mini-review
Keywords:
stroke, stem cells, clinical trialsAbstract
Ischemic stroke is a leading cause of death worldwide. Stem cell therapy becomes more attractive due to its possible therapeutic effect on stroke. Promising results have been observed in animal models of ischemic stroke, with evidence of significant benefits. Their beneficial effects might be due to cell replacement, neuroprotection, endogenous neurogenesis, angiogenesis, and modulation on inflammation and immune response. However, a number of issues remain unanswered, and further investigation of these will be imperative in the ongoing research for an effective, feasible and safe cell-based therapy. This review will discuss stem cell therapy in ischemic stroke, including evidence from current clinical trials.
References
Bourn J, Hudson J, Scharaschkin A et al. National Audit Office. Reducing Brain Damage: Faster Access to Better. Stroke Care 2005;1–60.
Reubinoff BE, Pera MF, Fong CY, et al. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotech 2000;18(4):399–404.
Ming GL, Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 2011;70(4):687–702.
Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005;57(6):874-882.
Honmou O, Houkin K, Matsunaga T et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain
2011;134(6):1790–1807.
Jiang Y, Zhu W, Zhu J et al. Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of lesion artery in patients with stroke in the
territory of middle cerebral artery. Cell Transplant 2013;22(12):2291-2298.
Bhasin A, Padma Srivastava MV, Mohanty S et al. Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg 2013;115(7):1003–1008.
Banerjee S, Bentleyb P, Hamadyc M et al. Intraarterial immunoselected CD34 stem cells for acute ischemic stroke. Stem Cells Translational Medicine,
August 2014. DOI: 10.5966/sctm.2013-0178
Zhao T, Zhang ZN, Rong Z et al. Immunogenicity of induced pluripotent stem cells. Nature 2011;474(7350): 212–216.
Yamashita T, Kawai H, Tian F et al. Tumorigenic development of induced pluripotent stem cells in ischemic mouse brain. Cell Transplant 2011;20(6):883–891.
Lappalainen RS, Narkilahti S, Huhtala T et al. The SPECT imaging shows the accumulation of neural progenitor cells into internal organs after systemic administration in middle cerebral artery occlusion rats. Neurosci Lett 2008;440(3):246–250.
Levitt JM, Lodhi IJ, Nguyen PK et al. Low-dose sulfur mustard primes oxidative function and induces apoptosis in human polymorphonuclear leukocytes.
Intl Immunopharmacol 2003;3(5):747–756.
Khalil MM, Tremoleda JL, Bayomy TB et al. Molecular SPECT imaging: an overview. Intl J Mol Imaging 2011;Article ID796025.
Jin K, Mao X, Xie L et al. Transplantation of human neural precursor cells in Matrigel scaffolding improves outcome from focal cerebral ischemia after delayed
postischemic treatment in rats. J Cereb Blood Flow Metab 2010;30(3):534–544.
Doeppner TR, Ewert TA, Tonges L et al. Transduction of neural precursor cells with TAT-heat shock protein 70 chaperone: therapeutic potential against ischemic stroke after intrastriatal and systemic transplantation. Stem Cells 2012;30(6):1297–1310.
Lalu MM, McIntyre L, Pugliese C et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE 2012;7(10):Article ID e47559.
Downloads
Published
How to Cite
Issue
Section
License
ข้อความภายในบทความที่ตีพิมพ์ในวารสารสมาคมโรคหลอดเลือดสมองไทยเล่มนี้ ตลอดจนความรับผิดชอบด้านเนื้อหาและการตรวจร่างบทความเป็นของผู้นิพนธ์ ไม่เกี่ยวข้องกับกองบรรณาธิการแต่อย่างใด การนำเนื้อหา ข้อความหรือข้อคิดเห็นของบทความไปเผยแพร่ ต้องได้รับอนุญาตจากกองบรรณาธิการอย่างเป็นลายลักษณ์อักษร ผลงานที่ได้รับการตีพิมพ์ในวารสารเล่มนี้ถือเป็นลิขสิทธิ์ของวารสาร
